BACKGROUND: Current therapies for adenocarcinoma of the pancreas do not improve the life expectancy of patients. METHODS: In a non-randomized pilot trail we tested whether a local therapy based upon an adenoviral gene transfer of wild type p53 in combination with gemcitabine administration would be safe in patients with liver metastases due to pancreatic carcinoma. We report on the clinical course of three patients with respect to safety, tolerability and tumor response. RESULTS: Transient grade III toxicities occurred with fever, leucopenia, elevation of AP, ALT, AST, GGT, while grade IV toxicity occurred for bilirubin only. Laboratory tests suggested disseminated intravascular coagulation in all three patients, but fine needle biopsies of liver did not show any histological evidence of thrombus or clot formation. Progression of liver metastases was documented in one and stable disease in another patient two months after treatment. However, a major improvement with regression of the indexed lesion by 80% occurred in a third patient after a single administration of 7.5 x 10(12) viral particles, and time to progression was extended to six months. CONCLUSION: The combination therapy of viral gene transfer and chemotherapy temporarily controls and diminishes tumor burden. Improvement of the toxicity profile is necessary. Further trials are warranted to improve treatment and life expectancy of patients suffering from fatal diseases such as pancreatic carcinoma.
BACKGROUND: Current therapies for adenocarcinoma of the pancreas do not improve the life expectancy of patients. METHODS: In a non-randomized pilot trail we tested whether a local therapy based upon an adenoviral gene transfer of wild type p53 in combination with gemcitabine administration would be safe in patients with liver metastases due to pancreatic carcinoma. We report on the clinical course of three patients with respect to safety, tolerability and tumor response. RESULTS: Transient grade III toxicities occurred with fever, leucopenia, elevation of AP, ALT, AST, GGT, while grade IV toxicity occurred for bilirubin only. Laboratory tests suggested disseminated intravascular coagulation in all three patients, but fine needle biopsies of liver did not show any histological evidence of thrombus or clot formation. Progression of liver metastases was documented in one and stable disease in another patient two months after treatment. However, a major improvement with regression of the indexed lesion by 80% occurred in a third patient after a single administration of 7.5 x 10(12) viral particles, and time to progression was extended to six months. CONCLUSION: The combination therapy of viral gene transfer and chemotherapy temporarily controls and diminishes tumor burden. Improvement of the toxicity profile is necessary. Further trials are warranted to improve treatment and life expectancy of patients suffering from fatal diseases such as pancreatic carcinoma.
Authors: M Bouvet; R J Bold; J Lee; D B Evans; J L Abbruzzese; P J Chiao; D J McConkey; J Chandra; S Chada; B Fang; J A Roth Journal: Ann Surg Oncol Date: 1998-12 Impact factor: 5.344
Authors: Núria Morral; Wanda K O'Neal; Karen Rice; M Michelle Leland; Pedro A Piedra; Estuardo Aguilar-Córdova; K Dee Carey; Arthur L Beaudet; Claire Langston Journal: Hum Gene Ther Date: 2002-01-01 Impact factor: 5.695
Authors: Nagy Habib; Hosny Salama; Ahmed Abd El Latif Abu Median; Ilia Isac Anis; Rasha Ahmed Abd Al Aziz; Catherine Sarraf; Ragai Mitry; Roman Havlik; Prem Seth; Jack Hartwigsen; Reva Bhushan; Joanna Nicholls; Steen Jensen Journal: Cancer Gene Ther Date: 2002-03 Impact factor: 5.987
Authors: Richard E Buller; Ingo B Runnebaum; Beth Y Karlan; Jo Ann Horowitz; Mark Shahin; Thomas Buekers; Stan Petrauskas; Rolf Kreienberg; Dennis Slamon; Mark Pegram Journal: Cancer Gene Ther Date: 2002-07 Impact factor: 5.987
Authors: Richard E Buller; Mark S Shahin; Jo Ann Horowitz; Ingo B Runnebaum; Vikas Mahavni; Stan Petrauskas; Rolf Kreienberg; Beth Karlan; Dennis Slamon; Mark Pegram Journal: Cancer Gene Ther Date: 2002-07 Impact factor: 5.987
Authors: Richard E Morrissey; Christopher Horvath; Eileen A Snyder; James Patrick; Nathaniel Collins; Ellen Evans; James S MacDonald Journal: Toxicol Sci Date: 2002-02 Impact factor: 4.849
Authors: Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski Journal: J Process Control Date: 2011-03-01 Impact factor: 3.666
Authors: Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad Journal: Curr Cancer Drug Targets Date: 2010-05 Impact factor: 3.428